A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-MM5
- Sponsors Takeda Oncology
- 11 Nov 2019 Planned End Date changed from 31 Mar 2023 to 11 Dec 2020.
- 11 Nov 2019 Planned primary completion date changed from 30 Nov 2021 to 17 Sep 2020.
- 11 Nov 2019 Status changed from recruiting to active, no longer recruiting.